StockWatch
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
AcquisitionsJul 9, 2026, 08:17 AM

Stereotaxis Completes Robocath Acquisition for Approx. $20M

AI Summary

Stereotaxis, Inc. announced the completion of its previously disclosed acquisition of Robocath, a French robotic technologies innovator, on July 7, 2026. The transaction was valued at approximately $20 million, paid in a combination of cash and Stereotaxis Common Stock. In connection with the acquisition, Stereotaxis issued 1,469,485 shares of Common Stock and Purchaser Warrants for 4,575,143 shares, along with 225,000 shares to Robocath's financial advisor. The acquisition aims to integrate complementary technologies, strengthen Stereotaxis's leadership in endovascular robotics, and accelerate the development of next-generation robotic solutions.

Key Highlights

  • Stereotaxis completed the acquisition of Robocath on July 7, 2026.
  • The acquisition was for approximately $20 million in cash and Common Stock.
  • Stereotaxis issued 1,469,485 shares of Common Stock to Robocath securityholders.
  • Stereotaxis issued Purchaser Warrants for 4,575,143 shares of Common Stock.
  • An additional 225,000 shares of Common Stock were issued to Robocath's financial advisor.
  • Potential earnout consideration of up to $25.0 million may be issued based on performance targets.
  • The acquisition combines complementary technologies to accelerate robotic solutions development.